BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35269773)

  • 21. Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members.
    Kittaneh M; Berkelhammer C
    J Transl Med; 2018 Jul; 16(1):194. PubMed ID: 30001711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy.
    Boffetta P; Righi L; Ciocan C; Pelucchi C; La Vecchia C; Romano C; Papotti M; Pira E
    Ann Oncol; 2018 Feb; 29(2):484-489. PubMed ID: 29206890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
    Sneddon S; Dick I; Lee YCG; Musk AWB; Patch AM; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
    Lung Cancer; 2018 May; 119():64-70. PubMed ID: 29656754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma.
    Napolitano A; Pellegrini L; Dey A; Larson D; Tanji M; Flores EG; Kendrick B; Lapid D; Powers A; Kanodia S; Pastorino S; Pass HI; Dixit V; Yang H; Carbone M
    Oncogene; 2016 Apr; 35(15):1996-2002. PubMed ID: 26119930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Malignant mesothelioma and constitutional BAP1 gene mutations].
    Neviere Z; Berthet P; Polycarpe F; Dubos-Arvis C; Dô P; Gervais R
    Rev Mal Respir; 2019 Feb; 36(2):241-248. PubMed ID: 30686559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
    Alakus H; Yost SE; Woo B; French R; Lin GY; Jepsen K; Frazer KA; Lowy AM; Harismendy O
    J Transl Med; 2015 Apr; 13():122. PubMed ID: 25889843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
    Betti M; Aspesi A; Biasi A; Casalone E; Ferrante D; Ogliara P; Gironi LC; Giorgione R; Farinelli P; Grosso F; Libener R; Rosato S; Turchetti D; Maffè A; Casadio C; Ascoli V; Dianzani C; Colombo E; Piccolini E; Pavesi M; Miccoli S; Mirabelli D; Bracco C; Righi L; Boldorini R; Papotti M; Matullo G; Magnani C; Pasini B; Dianzani I
    Cancer Lett; 2016 Aug; 378(2):120-30. PubMed ID: 27181379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline BAP1 mutations predispose to malignant mesothelioma.
    Testa JR; Cheung M; Pei J; Below JE; Tan Y; Sementino E; Cox NJ; Dogan AU; Pass HI; Trusa S; Hesdorffer M; Nasu M; Powers A; Rivera Z; Comertpay S; Tanji M; Gaudino G; Yang H; Carbone M
    Nat Genet; 2011 Aug; 43(10):1022-5. PubMed ID: 21874000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: Identification of a novel BAP1 germline variant.
    Shinozaki-Ushiku A; Kohsaka S; Kage H; Oda K; Miyagawa K; Nakajima J; Aburatani H; Mano H; Ushiku T
    Pathol Int; 2020 Oct; 70(10):775-780. PubMed ID: 32583627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
    Carbone M; Adusumilli PS; Alexander HR; Baas P; Bardelli F; Bononi A; Bueno R; Felley-Bosco E; Galateau-Salle F; Jablons D; Mansfield AS; Minaai M; de Perrot M; Pesavento P; Rusch V; Severson DT; Taioli E; Tsao A; Woodard G; Yang H; Zauderer MG; Pass HI
    CA Cancer J Clin; 2019 Sep; 69(5):402-429. PubMed ID: 31283845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
    Zauderer MG; Bott M; McMillan R; Sima CS; Rusch V; Krug LM; Ladanyi M
    J Thorac Oncol; 2013 Nov; 8(11):1430-3. PubMed ID: 24128712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma.
    Paajanen J; Bueno R; De Rienzo A
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
    Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
    Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
    Rusch A; Ziltener G; Nackaerts K; Weder W; Stahel RA; Felley-Bosco E
    Lung Cancer; 2015 Jan; 87(1):77-9. PubMed ID: 25468148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
    Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
    Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma.
    Lai J; Zhou Z; Tang XJ; Gao ZB; Zhou J; Chen SQ
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
    Kalra N; Zhang J; Thomas A; Xi L; Cheung M; Talarchek J; Burkett S; Tsokos MG; Chen Y; Raffeld M; Miettinen M; Pastan I; Testa JR; Hassan R
    BMC Cancer; 2015 May; 15():376. PubMed ID: 25952750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular pathogenesis of malignant mesothelioma.
    Sekido Y
    Carcinogenesis; 2013 Jul; 34(7):1413-9. PubMed ID: 23677068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
    Kettunen E; Savukoski S; Salmenkivi K; Böhling T; Vanhala E; Kuosma E; Anttila S; Wolff H
    BMC Cancer; 2019 May; 19(1):507. PubMed ID: 31138176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.